This trial is active, not recruiting.

Condition alopecia
Treatment roxithromycin
Sponsor Hamamatsu University
Start date May 2005
End date January 2007
Trial size 20 participants
Trial identifier NCT00197379, 16-61


The purpose of this study is exploiting the new drugs for androgenetic alopecia because there are still no effective and safe topical drug for androgenetic alopecia. Roxithomycin is one of the macrolide antibiotics that has immunomodulatory effects. We firstly found that roxithromycin increases the rate of murine and human hair follicle elongation in vitro. Therefore, we apply this drug on this disease therapy.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model crossover assignment
Masking open label
Primary purpose treatment

Secondary Outcomes

Pathological study taken from lesional scalp skin.
time frame: One year

Eligibility Criteria

Male or female participants at least 20 years old.

Inclusion Criteria: - Androgenetic alopecia Exclusion Criteria: - Cicatricial alopecia - Allergy to roxitromycin - Children (19years old or younger) - Pregnant female

Additional Information

Official title The Study for New Effect of Roxithromycin on Androgenetic Alopecia.
Description The topical therapy for androgenetic alopecia is still not enough to improve cosmetically. Thereforem we try to find new effective and safe topical therapy for this disease. Roxithromycin has not only antibacterial action but also immunomodulatory and anti-inflamatory potency. For example, roxitromycin inhibits T cell responces to mitogens and production of cytokines, IL-2 and IL-5. We firstly found that roxitromycin increased human and murine hair elongation in vitro to inhibit apoptosis of hair bulb. Then, we wish to apply roxithromycin on the therapy for androgenetic alopecia.
Trial information was received from ClinicalTrials.gov and was last updated in July 2010.
Information provided to ClinicalTrials.gov by Hamamatsu University.